Shanghai Hile Bio-Technology Balance Sheet Health
Financial Health criteria checks 4/6
Shanghai Hile Bio-Technology has a total shareholder equity of CN¥1.2B and total debt of CN¥60.9M, which brings its debt-to-equity ratio to 5%. Its total assets and total liabilities are CN¥1.6B and CN¥398.0M respectively.
Key information
5.0%
Debt to equity ratio
CN¥60.91m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥221.20m |
| Equity | CN¥1.23b |
| Total liabilities | CN¥398.05m |
| Total assets | CN¥1.62b |
Recent financial health updates
Recent updates
Health Check: How Prudently Does Shanghai Hile Bio-Technology (SHSE:603718) Use Debt?
Dec 17
Shanghai Hile Bio-Technology Co., Ltd.'s (SHSE:603718) 28% Share Price Surge Not Quite Adding Up
Nov 14Investor Optimism Abounds Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718) But Growth Is Lacking
Sep 30There May Be Some Bright Spots In Shanghai Hile Bio-Technology's (SHSE:603718) Earnings
May 06Earnings Not Telling The Story For Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718)
Apr 29Financial Position Analysis
Short Term Liabilities: 603718's short term assets (CN¥1.2B) exceed its short term liabilities (CN¥371.0M).
Long Term Liabilities: 603718's short term assets (CN¥1.2B) exceed its long term liabilities (CN¥27.0M).
Debt to Equity History and Analysis
Debt Level: 603718 has more cash than its total debt.
Reducing Debt: 603718's debt to equity ratio has increased from 0% to 5% over the past 5 years.
Debt Coverage: 603718's debt is well covered by operating cash flow (116.2%).
Interest Coverage: Insufficient data to determine if 603718's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 19:27 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shanghai Hile Bio-Technology Co., Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jia Chen | Changjiang Securities Co. LTD. |
| Jiao Chen | Industrial Securities Co. Ltd. |
| Yanhai Gong | SWS Research Co., Ltd. |